Amsterdam Molecular, uniQure deal

Amsterdam Molecular's board unanimously recommended dissolving the company's assets into newco uniQure in a stock deal. Amsterdam said it is facing a "precarious" financial position with cash expected to last until April and the deal is "the only viable way to secure a capital injection." Amsterdam shareholders will receive one new uniQure depository receipt (DR) for every outstanding Amsterdam Molecular share. Amsterdam Molecular will delist. The uniQure DRs will not be listed.

Amsterdam said uniQure will continue to invest in Amsterdam's Phase I/II compound AMT-060 for hemophilia B, and preclinical compounds: AMT-090 for Parkinson's disease (PD) and AMT-021 for acute intermittent porphyria. AMT-060 is an adeno-associated viral (AAV) vector encoding the Factor IX gene. AMT-090 is an AAV vector encoding the glial cell-derived neurotrophic factor (GDNF) gene and AMT-021 is an AAV vector encoding the porphobilinogen deaminase gene. ...